IMAGE

Fig. 6

ID
ZDB-IMAGE-240703-71
Source
Figures for Choleva et al., 2024
Image
Figure Caption

Fig. 6 Antibodies against the PTPRZ1 FNIII domain inhibit PTN and VEGFA165-induced endothelial cell migration and signaling. (A) HUVEC were incubated in the presence or absence of anti-FNIII (10 ng/ml) or mouse IgG (10 ng/ml) for 24 h. Total cell lysates were then immunoprecipitated by using an antibody against the C-terminus of PTPRZ1 or non-specific IgG and analyzed by Western blot using an antibody against PTN or VEGFA. The content of β-actin in the corresponding lysate was used as a loading control. Representative images from two independent experiments are shown. (B) Migration of HUVEC in the presence or absence of PTN (100 ng/ml), VEGFA165 (10 ng/ml), and/or anti-FNIII (10 ng/ml). Results are expressed as mean ± SD (n = 4) of the percent number of migrated cells compared to the untreated cells (set as default 100%). (C) Migration of HUVEC in the presence or absence of PTN, VEGFA165, and/or anti-PTPRZ1 (10 ng/ml). Results are expressed as mean ± SD (n = 5 for VEGFA165 and 3 for PTN) of the percent number of migrated cells compared to the untreated cells (set as default 100%). (D) HUVEC were treated with VEGFA165 and/or anti-PTPRZ1 for 10 min and cell lysates were analyzed by antibodies against Akt phosphorylated at Ser473 (pAkt), and total Akt (tAkt). A representative Western blot is shown. Results are expressed as mean ± SD (n = 2) of the percent pAkt/tAkt ratio compared to untreated HUVEC (set as default = 100). (E) HUVEC were treated with VEGFA165 and/or anti-PTPRZ1 for 10 min and cell lysates were analyzed by antibodies against VEGF receptor 2 phosphorylated at Tyr1175 (pVEGFR2), and total VEGF receptor 2 (VEGFR2). A representative Western blot is shown. Results are expressed as mean ± SD (n = 3) of the percent pVEGFR2/VEGFR2 ratio compared to untreated HUVEC (set as default = 100).

Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image.

Reprinted from European Journal of Pharmacology, 977, Choleva, E., Menounou, L., Ntenekou, D., Kastana, P., Tzoupis, Η., Katraki-Pavlou, S., Drakopoulou, M., Spyropoulos, D., Andrikopoulou, A., Kanellopoulou, V., Enake, M.K., Beis, D., Papadimitriou, E., Targeting the interaction of pleiotrophin and VEGFA165 with protein tyrosine phosphatase receptor zeta 1 inhibits endothelial cell activation and angiogenesis, 176692, Copyright (2024) with permission from Elsevier. Full text @ Eur. J. Pharmacol.